公开(公告)号：EP1940401B1

公开(公告)日：2012-07-11

申请号：EP06836311.8

申请日：2006-10-13

Applicant: Merck Sharp & Dohme Corp.

Inventor： BAKSHI, Raman, K. ,  DELLUREFICIO, James, P. ,  DOBBELAAR, Peter, H. ,  GUO, Liangqin ,  HE, Shuwen ,  HONG, Qingmei ,  NARGUND, Ravi, P. ,  YE, Zhixiong

IPC: A61K31/438 ,  A61K31/5377 ,  C07D221/20 ,  C07D413/02 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D491/08 ,  C07D519/00 ,  C07D491/107

CPC classification number: C07D401/14 ,  C07D221/20 ,  C07D405/14 ,  C07D413/14 ,  C07D471/10 ,  C07D491/08 ,  C07D491/107 ,  C07D519/00

Abstract: Certain novel N-acylated spiropiperidine derivatives are ligands of the human melanocortin receptor(s) and, in particular, are selective ligands of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of MC-4R, such as obesity, diabetes, nicotine addiction, alcoholism, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

公开(公告)号：EP3371191B1

公开(公告)日：2020-08-26

申请号：EP16860602.8

申请日：2016-10-25

Applicant: Merck Sharp & Dohme Corp.

Inventor： WITTER, David, J. ,  BIFTU, Tesfaye ,  BIJU, Purakkattle ,  BOGEN, Stephane, L. ,  HONG, Qingmei ,  HUANG, Chunhui ,  HUANG, Xianhai ,  LI, Bing ,  PARK, Min, K. ,  SLOMAN, David, L.

IPC: C07D491/10 ,  C07D498/08 ,  C07D471/04 ,  C07D519/00 ,  A61P35/02 ,  A61K31/5517

公开(公告)号：EP2909221A1

公开(公告)日：2015-08-26

申请号：EP13818854.5

申请日：2013-10-15

Applicant: Merck Sharp & Dohme Corp.

Inventor： GIRIJAVALLABHAN, Vinay ,  BOGEN, Stephane ,  TRUONG, Quang, T. ,  CHEN, Ping ,  KEREKES, Angela ,  BENNETT, Frank ,  ESPOSITE, Sara ,  HONG, Qingmei ,  DAVIES, Ian

IPC: C07H19/067 ,  C07H19/073 ,  C07H19/10 ,  A61K31/7068 ,  A61K31/7072 ,  A61P31/14 ,  C07H19/06

CPC classification number: C07H19/06 ,  A61K31/7068 ,  A61K31/7072 ,  A61K45/06 ,  C07H19/067 ,  C07H19/073 ,  C07H19/10

Abstract: The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R
1 , R
2 and R
3 , are as defined herein. The present invention also relates to compositions comprising at least one 2'-Methyl Substituted Nucleoside Derivative, and methods of using the 2'-Methyl Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

公开(公告)号：EP3226688A1

公开(公告)日：2017-10-11

申请号：EP15865691.8

申请日：2015-12-01

Applicant: Merck Sharp & Dohme Corp.

Inventor： FISCHER, Christian ,  BOGEN, Stephane, L. ,  CHILDERS, Matthew, L. ,  LLINAS, Francesc Xavier Fradera ,  ELLIS, J. Michael ,  ESPOSITE, Sara ,  HONG, Qingmei ,  HUANG, Chunhui ,  KIM, Alexander, J. ,  LAMPE, John, W. ,  MACHACEK, Michelle, R. ,  MCMASTERS, Daniel, R. ,  OTTE, Ryan, D. ,  PARKER, Dann, L., Jr. ,  REUTERSHAN, Michael ,  SCIAMMETTA, Nunzio ,  SHAO, Pengcheng, P. ,  SLOMAN, David, L. ,  UJJAINWALLA, Feroze ,  WHITE,Catherine ,  WU, Zhicai

IPC: A01N43/00

CPC classification number: C07D498/08 ,  A01N43/00 ,  C07D471/04 ,  C07D471/08 ,  C07D498/04 ,  C07D498/10

Abstract: The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.

Abstract translation: 本发明涉及作为一种或多种突变IDH酶抑制剂的式（I）三环化合物：（I）。 本发明还涉及本文所述的三环化合物在潜在治疗或预防其中涉及一种或多种突变IDH酶的癌症中的用途。 本发明还涉及包含这些化合物的组合物。 本发明还涉及这些组合物在潜在的预防或治疗这些癌症中的用途。

公开(公告)号：EP3972590A1

公开(公告)日：2022-03-30

申请号：EP20809677.6

申请日：2020-05-18

Applicant: Merck Sharp & Dohme Corp.

Inventor： HONG, Qingmei ,  IMBRIGLIO, Jason, E. ,  KEREKES, Angela, D. ,  KHAN, Tanweer ,  LANKIN, Claire ,  LI, Derun ,  LIANG, Rui ,  SHAO, Pengcheng Patrick ,  WU, Zhicai ,  XIONG, Yusheng ,  YOUM, Hyewon ,  YU, Yang ,  KURISSERY, Anthappan Tony ,  KOMANDURI, Venukrishnan ,  YE, Feng.

IPC: A61K31/415 ,  A61K31/4192 ,  A61K31/42

公开(公告)号：EP3371191A1

公开(公告)日：2018-09-12

申请号：EP16860602.8

申请日：2016-10-25

Applicant: Merck Sharp & Dohme Corp.

Inventor： WITTER, David, J. ,  BIFTU, Tesfaye ,  BIJU, Purakkattle ,  BOGEN, Stephane, L. ,  HONG, Qingmei ,  HUANG, Chunhui ,  HUANG, Xianhai ,  LI, Bing ,  PARK, Min, K. ,  SLOMAN, David, L.

IPC: C07D487/04 ,  C07D487/12

Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.